Market Research Logo

Medical Marijuana-from Illicit To Legal And Beyond To Pharmaceuticals -Global Markets, Competitors And Opportunities:2015-2020 Analysis And Forecasts

Medical Marijuana-from Illicit To Legal And Beyond To Pharmaceuticals -global Markets, Competitors And Opportunities:2015-2020 Analysis And Forecasts

The objective of this report is to provide a detailed analysis of the global market for Medical Marijuana. It is also to provide a comprehensive analysis of the leading companies producing these products, as well as the competitive environment they operate in. Marijuana (cannabis) remains a controversial drug in the twenty-first century. However, the potential role of specific cannabinoids for medical benefits will be revealed as the twenty-first century matures.

Marijuana is the most widely cultivated illicit drug plant worldwide. The international legal framework on drug control is provided by three United Nations Conventions, which instruct countries to limit drug supply and use to medical and scientific purposes. Nevertheless, there continues to be increasing debate over decriminalization, or even legalization of cannabis in particular.

This report provides an estimate of global cannabis production both in volume and value during the 2015-2020 period. The illicit use of marijuana dwarfs the medical use and that probably always will be the case. But to put global cannabis production in perspective, it is bigger than retail sales of all OTC (over-the-counter) analgesic pharmaceuticals by a factor of 9 and sales of pain medication pharmaceuticals by a factor of 25.

23 U.S. states and the District of Columbia now have legalized medical marijuana, and two states (Colorado and Washington state) allow for adult use (commonly referred to as recreational use). However, the focus in this report is on the Canada medical marijuana market, which is a new, emerging growth industry. The medical marijuana space in Canada, which went into effect in April 2014, has created conditions for a new highly regulated commercial industry with a limited amount of suppliers vetted extensively by Health Canada. Over $100 million in investment dollars have flowed into the Canadian medical marijuana industry already.

The future of medical marijuana lies in pharmaceutical products for the management of neuropathic pain, hypertension, post-stroke neuroprotection, multiple sclerosis, epilepsy, cancer, and other disorders.


  • EXECUTIVE SUMMARY
  • INTRODUCTION
    • Report Objective
    • Methodology and Sources
    • Statistical Notes
  • MEDICAL MARIJUANA
    • Introduction
    • Used for Thousands of Years
    • Cannabis Sativa Plant
    • Prevalence of Use
      • Table Lifetime Use of Marijuana by Country: 2007
    • Method of Consumption
    • Cannabis Use with Other Drugs
    • Cannabinoids
      • Table Types of Cannabinoids
    • Endocannabinoid System
    • Benefits of Medical Marijuana
      • Table Potential Benefits of Cannabis Based on Research Studies
    • Medical Adverse Effects
      • Table Potential Adverse Effects of Marijuana
    • Dental Effects of Cannabis
    • Pulmonary Effects
    • Cannabis and Cancer
    • Cardiovascular Effects
    • Psychiatric Adverse Effects
      • Cannabis and Neurodevelopment Effects
    • Cannabis and ADHD
    • Cannabis Dependence
      • Table DSM-IV-TR Cannabis Use and Induced Disorders
    • Cannabis Withdrawal Syndrome
    • Addiction
    • Cannabis and Psychosis
  • GLOBAL CANNABIS MARKET
    • Most Widely Cultivated Illicit Drug Plant
      • Table Worldwide Number (Millions) and Prevalence (%) of Users by Type of Illicit Drug: 2012
    • Indica vs. Sativa
    • THC vs. CBD
    • Main Cannabis Products
    • Legal Issues
    • Netherlands Laws
    • United States Laws
    • Uruguay Laws
      • Table Comparison of Marijuana Laws in the Netherlands, Colorado State, Washington State, Uruguay
    • Production and Yields Highly Variable
    • Production Estimation Issues
    • UNDOC Estimates
      • Table World Cannabis Herb and Resin Production (Hectares, Metric Tons): 2003-2008
    • Global Cannabis Production
      • Table Global Cannabis Production Volume (MT), Value (USD) and Average Selling Price (Million USD/MT): 2015-2020
    • Global Cannabis Production by Region
      • Table Global Cannabis Production Volume by Region (Metric Tons): 2015
    • North America Cannabis Production
      • Table North America Cannabis Production Volume (MT), Value (USD) and Average Selling Price (Million USD/MT): 2015
    • Marijuana Market vs. OTC Analgesic and Pain Pharmaceuticals Markets
      • Table Global Sales of Over-the-Counter (OTC) Pharmaceuticals by Application (USD Million): 2013
    • Canada Marijuana Market vs. U.S. Market
      • Legalization and Decriminalization
      • California Medical Marijuana Market
        • Table California Medical Marijuana Market Highlights
    • Canadian Market Structure More Favorable for Producers
    • Illicit Marijuana Production vs. Medical Marijuana Production
      • Table Canada Licensed Producer Production by Company (kg): 2014-2018
    • Colorado Black Market for Marijuana
  • CANADA MEDICAL MARIJUANA MARKET
    • New Emerging Growth Industry
      • Table Therapeutic Uses Of Cannabis
    • Modern History of Medical Marijuana in Canada
      • Table History of Canada Medical Marijuana Regulations: 1996-2014
    • MMAR vs. MMPR - Regulatory Overhaul Following Safety Concerns and Abuse
    • Why MMAR Was Overhauled
    • Objectives of MMPR
      • Table Key Differences Between MMAR and MMPR
    • Marihuana for Medical Purposes Regulations - The New System
    • Injunction Explained
    • Patient Application Streamlined
    • Prescription Process Under MMPR
      • Table Sample MMPR Application Form
    • Shipping/Packaging Requirements
    • Licensing Process Under MMPR
    • Growing Enrollment Numbers Points to Strong Growth
    • Health Canada Projected Demand
    • How HC Made Its Forecasts Is Somewhat Unknown
    • Canada Forecast Patient Growth
    • U.S. Forecast Patient Growth
    • Growth Rates from A Low Base.
    • Market in 2024
      • Table Canada Medical Marijuana Market in 2024 Using Different Patient Number and Price Assumptions (Number, 2014 C$ /Gram)
    • Proposed Expansion Plans of LPs May Satisfy Demand
      • Table Canada Public LPs Expected Production Capacity (kg): 2015
    • More than C$100 Million Invested
    • Product Pricing Varies by LP
    • Compassionate Pricing Is Not Mandatory
    • Licensed Producers
    • Good To Be an LP
      • Table 15 Current Health Canada Licensed Producers (Location, Description, Capacity, Patients): 1Q 2015
    • Physician Role Is Very Important
    • Physician Role Should Not Be Overstated
    • MMAR Physician Authorizations
    • Physician Penetration Under MMPR
    • Health Canada View on Medical Marijuana
    • College of Family Physicians of Canada Prescribing Guidelines
    • Patients Using Medical Marijuana in Canada by Ailment
    • Soils vs. Hydroponic
    • Indoor vs. Outdoor
    • Production Cycle
    • Cost of Production
    • Infused Products Not Allowed Yet
    • Industry Catalysts
      • Consolidation More Likely Than Acquisition
    • Edibles Legalization
    • Edibles Issues
    • Insurance Coverage
    • Recreational Legalization
    • Potential Risks
      • Legislation Changes
    • Enterprise Valuations
    • Adoption Rates Still Uncertain
    • Product Quality and Public Perception
  • COMPANY PROFILES
    • Aphria Inc
      • Company Overview
      • Medical Marijuana
        • Table Aphria Product Offerings
    • Bedrocan Cannabis Corp.
      • Company Overview
      • Strategy
        • Table Bedrocan Operations Timeline: 2012-2015
      • Medical Marijuana
      • Competitive Advantages
      • Bedrocan BV
      • Advantages to Bedrocan BV Partnership
      • License Agreement Lowers Risk
      • License Agreement Provides Upside
      • South American Countries Looking to Legalize
      • Bedrocan Product Suite
      • Bedrocan (22% THC, <1% CBD)
      • Bedropuur (20% and 24% THC, <1% CBD)
      • Bedica (14% and 17% THC, <1% CBD)
      • Bediol (6.5% THC, 8% CBD)
      • Bedrolite (<0.5% THC, 9% CBD)
      • Small Product Suite
      • CFPC Preliminary Guidelines
      • Facilities
      • Import Facility
        • Table Bedrocan Cannabis Corp. Import Facility Features
      • Domestic Production Facility
        • Table Bedrocan Cannabis Corp. Domestic Facility Features
      • Acquisition for Facility Growth
      • BV Import Schedule
      • State of the Art Growing Operations
      • Production Flow
      • Production Ramp
      • Annual Sales Volume
      • Cost Per Gram
      • Marketing Strategy
      • Retail Prices
      • Patient Sign up Process
        • Table Bedrocan Cannabis Registration Application Form
      • Current Patient Composition
      • Wait List
      • Patient Count Growing
      • Patient Consumption Rates
      • Physician Outreach and Medical Advisory Board
      • ISO-9000 Certified
      • Standardization Advantages
      • Management and Directors Bring Relationships, Experience
      • Private Placement
      • Enterprise Value
      • Financials
        • Table Bedrocan Cannabis Corp. Income Statement: 2015-2019
    • Cannabis Science, Inc.
      • Company Overview
      • Medical Marijuana
      • Key Target-Based Actions
      • Key Technologies
      • Drugs
      • CS-TATI-1
      • Cannabinoid Compounds
      • Facilities
      • Collaborations
      • Acquisitions and Spin-Offs
      • Licensing Agreements
      • R&D
      • Financials
        • Table Cannabis Science, Inc. Income Statement: 2012-2014
    • GW Pharmaceuticals plc
      • Company Overview
      • Medical Marijuana
      • Sativex Multiple Sclerosis Market
        • Table Sativex Multiple Sclerosis Revenue Model : 2013-2027
      • Sativex Cancer Pain Market
        • Table Sativex Cancer Pain Revenue Model: 2013-2027
      • Epilepsy
        • Table Tuberous Sclerosis Complex Case Studies Show Compelling CBD Benefits in Highly Refractory Epilepsy Patients
      • Epidiolex Market
        • Table Epidiolex Revenue Model: 2013-2028
      • Inflammatory Bowel Disease (IBD)
        • Table Published Research Citing the Clinical Potential of Cannabis in Inflammatory Bowel Disease
      • Marijuana Use and IBD
      • Cannabinoid Receptor System and Immune Regulation
        • Table Inflammatory Bowel Disease by Type, Endocannabinoid Changes and Receptor Changes
      • Ulcerative Colitis Background
      • Ulcerative Colitis Subtypes
        • Table The Five Types of UC: Variability in Acute Presentation and Long Term Outcomes
      • Goal of Ulcerative Colitis Treatment
      • Ulcerative Colitis Market
      • Trials
        • Table GW Pharmaceutical Trials: 2014-2015
      • Financials
        • Table GW Pharmaceuticals Income Statement (GBP Million): 2011-2017
    • Mettrum Health Corp
      • Company Overview
      • Medical Marijuana
      • Facilities
      • Production
      • Bowmanville Facility
      • Second Bowmanville Facility
      • Creemore Facility
      • Monetizing Product Through Bowmanville
      • 500 kg License
      • Licensing No Longer A Constraint
      • Resuming Customer Acquisition
      • Market Strategy
        • Table Mettrum Spectrum Products
      • RTO And Private Placement
        • Table Mettrum Spectrum Use of Private Placement Proceeds
      • Profits Could Reach C$50 Million
      • Barriers To Entry Growing
      • Oilseed Works Purchase
      • Financials
        • Table Mettrum Health Corp. Income Statement: 2014-2019
    • OrganiGram Holdings Inc.
      • Company Overview
      • Medical Marijuana
      • Facilities
      • Capacity
      • Products
        • Table OrganiGram Current Product Offerings
        • Table OrganiGram Future Product Offerings
      • Marketing
      • Patients
      • Trauma Healing Centers Agreement
      • Financials
    • Tweed Marijuana Inc.
      • Company Overview
      • Initial Financing
      • Medical Marijuana
      • Facilities
      • Smiths Falls Facility
      • Security
      • Growing Equipment
      • Laboratory
      • Expansion Plans
      • Smith Falls Grow Operations
        • Table Smiths Falls Estimated Production Breakdown (kg)
      • Smiths Falls Capacity to Double
      • Mother Room Houses ~5,000 Plants
      • Smiths Falls Could Produce ~7,500 - 10,000 kg/Year
      • Tweed Farms
      • Tweed Farms Property
      • Tweed Farms Grow Operations
      • 70% Lower Costs
      • Capacity Estimated at ~2,900-3,700 kg Annually
        • Table Tweed Farms Estimated Production Breakdown (kg)
      • Factors Offsetting Benefits of Greenhouse Production
        • Table Factors Offsetting Benefits of Greenhouse Production
      • Product Offerings
        • Table Tweed Products and Prices
      • Pricing
      • Vaporizers
      • Radiation
      • Other Potential Revenue Streams
      • Sales and Marketing Strategy
      • Go-to-Market Strategy
      • Patient Acquisition
      • Medical Advisory Board
      • Canadian AIDS Society
      • Trade Events
      • Ownership
      • Financials
        • Table Tweed Marijuana Inc. Income Statement: 2014-2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report